← Eichor
Condition: Moderate To Severe Plaque Psoriasis Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Moderate To Severe Plaque Psoriasis

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Phase 2 Study of HB0017 in Psoriasis Patients
Phase 2 · 18 location(s) · Huabo Biopharm Co., Ltd. · NCT06592274A Study to Evaluate D-2570 in Participants With Moderate to Severe Plaque Psoriasis
Phase 2 · 20 location(s) · InventisBio Co., Ltd · NCT07489885A Safety and Pharmacokinetics Study of IDP-122 Lotion in Pediatric Participants With Plaque Psoriasis
Phase 4 · 9 location(s) · Bausch Health Americas, Inc. · NCT03987763A Study to Evaluate the Drug Levels, Efficacy and Safety of Deucravacitinib in Children and Adolescent Participants With
Phase 3 · 63 location(s) · Bristol-Myers Squibb · NCT04772079A Study to Evaluate Comparative Efficacy and Safety of Guselkumab in High-dose and Extended-interval Versus Standard-dos
NA · 1 location(s) · Second Affiliated Hospital, School of Medicine, Zhejiang Uni · NCT07532486A Phase 3 Clinical Study of QL2106 Injection
Phase 3 · 1 location(s) · Qilu Pharmaceutical Co., Ltd. · NCT07511647A Study of UA026 Tablets in Healthy Adult Subjects and Adult Subjects With Moderate to Severe Plaque Psoriasis
Phase 1 · 1 location(s) · Usynova Pharmaceuticals Ltd. · NCT07038720Study of SFA002 in Patients with Mild to Moderate Psoriasis Plaques
Phase 1 · 3 location(s) · SFA Therapeutics · NCT05642182A Pilot Study to Assess How Safe and Effective Oral Roflumilast is for Treating Moderate to Severe Psoriasis in Adults
Phase 2 · 1 location(s) · Ahmed Ibrahim · NCT07233291Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque Psoriasis
Phase 2 · 36 location(s) · Oruka Therapeutics, Inc. · NCT07290569A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Pa
Phase 4 · 40 location(s) · Eli Lilly and Company · NCT06857942To Check Comparison of Apremilast and Methotrexate Efficacy in Patients With Moderate to Severe Plaque Psoriasis Present
EARLY_Phase 1 · 1 location(s) · Syeda Sana Zaman · NCT07337434A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx®
Phase 1 · 14 location(s) · UCB Biopharma SRL · NCT06888193ILUMYA in Combination With HALOG Ointment 0.1% for Plaque Psoriasis.
Phase 4 · 1 location(s) · Psoriasis Treatment Center of Central New Jersey · NCT04347473Phase IV Study: Vunakizumab Efficacy and Safety in Moderate-to-severe Plaque Psoriasis
Phase N/A · 1 location(s) · First Hospital of China Medical University · NCT06696417A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants Wit
Phase 3 · 129 location(s) · Bristol-Myers Squibb · NCT06979453A Study to Assess the Effects of Switching From a Biologic Treatment to Tildrakizumab Using Patient-reported Outcomes in
Phase N/A · 1 location(s) · Almirall, S.A. · NCT06030076A Study to Evaluate Effectiveness and Safety of a TYK2 Inhibitor in Subjects With Moderate to Severe Plaque Psoriasis
NA · 1 location(s) · Usynova Pharmaceuticals Ltd. · NCT07234591A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase Ⅲ Study to Evaluate the Efficacy and Safety of WD-890
Phase 3 · 1 location(s) · Zhejiang Wenda Pharma Technology LTD. · NCT07672561Modifying PEST for Psoriatic Arthritis Screening
NA · 30 location(s) · Novartis Pharmaceuticals · NCT06382051Efficacy, Safety, Pharmacokinetics of ICP-488 in Patients With Moderate to Severe Plaque Psoriasis
Phase 3 · 46 location(s) · Beijing InnoCare Pharma Tech Co., Ltd. · NCT06842199Study to Assess Change in Quality of Life of Risankizumab Treatment in Adult Participants With Moderate-to-Severe Plaque
Phase N/A · 81 location(s) · AbbVie · NCT07039110A Study to Evaluate the Efficacy and Safety of CS32582 in Participants With Moderate to Severe Plaque Psoriasis
Phase 1/Phase 2 · 11 location(s) · Chipscreen Biosciences, Ltd. · NCT07129382An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis
Phase 2 · 24 location(s) · Oruka Therapeutics, Inc. · NCT07449702Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
Phase 3 · 394 location(s) · Bristol-Myers Squibb · NCT07116967Efficacy and Safety of ICP-332 Versus Placebo in Participants With Moderate to Severe Plaque Psoriasis
Phase 2 · 1 location(s) · Beijing InnoCare Pharma Tech Co., Ltd. · NCT07251998Dose Ranging Study of ORKA-002 in Patients With Moderate-to-Severe Plaque Psoriasis
Phase 2 · 34 location(s) · Oruka Therapeutics, Inc. · NCT07474792A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Ustekinumab in Children and Adolescents From 6 Ye
Phase 3 · 50 location(s) · UCB Biopharma SRL · NCT06425549A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis
Phase 3 · 40 location(s) · Takeda · NCT07250802A Study of Persistence to Guselkumab Treatment in Participants With Moderate-to-Severe Plaque Psoriasis in Romania
Phase N/A · 19 location(s) · Janssen Research & Development, LLC · NCT07582783
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.